PMID

Data

Article Title

Organization

Drug discovery strategies to outer membrane targets in Gram-negative pathogens.

Astrazeneca

N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.

Entasis Therapeutics

Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC.

Chiron

Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.

Taisho Pharmaceutical

Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline.

Novartis Institutes For Biomedical Research

Structure-based discovery of LpxC inhibitors.

Cubist Pharmaceuticals

Synthesis, Structure, and SAR of Tetrahydropyran-Based LpxC Inhibitors.

Astrazeneca

Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.

Pfizer

Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.

Pfizer

Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.

Novartis Institutes For Biomedical Research

In vivo and in vitro effect of androstene derivatives as 5a-reductase type 1 enzyme inhibitors.

National University of Mexico City

Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme.

Saarland University